WHO monitoring of Xpert MTB/RIF roll-out
Xpert MTB/RIF is an automated, cartridge-based nucleic amplification assay for the simultaneous detection of TB and rifampicin resistance directly from sputum in under two hours. The technology is based on the GeneXpert platform and was developed as a partnership between the Foundation for Innovative New Diagnostics (FIND), Cepheid Inc. and the University of Medicine and Dentistry of New Jersey, with support from the US National Institutes of Health. WHO recommended use of the technology in December 2010 and is monitoring the global roll-out of the technology to promote coordination.
The TBXpert Project, a new three-year UNITAID-funded collaboration, will make available up to USD25.9 million for roll-out of the Xpert MTB/RIF technology to 21 recipient countries. The TBXpert Project will be executed by the WHO Stop TB Department and the Stop TB Partnership secretariat.
Global summary statistics of procurement
Available map indicators:
- whether country has ordered at least one GeneXpert instrument
- total number of procured GeneXpert modules
- total number of procured Xpert MTB/RIF cartridges
- More details on concessional prices and eligible countries can be found on the FIND (Foundation for Innovative New Diagnostics) web site